Holen Sie sich die Stockscreener-App
11.23
1.06%
-0.12
Schlusskurs vom Vortag:
$11.35
Offen:
$11.32
24-Stunden-Volumen:
145.74K
Relative Volume:
0.53
Marktkapitalisierung:
$561.51M
Einnahmen:
$62.02M
Nettoeinkommen (Verlust:
$-45.65M
KGV:
-12.21
EPS:
-0.92
Netto-Cashflow:
$-9.60M
1W Leistung:
-2.60%
1M Leistung:
+5.64%
6M Leistung:
+19.98%
1J Leistung:
+9.67%
1-Tages-Spanne:
$11.16
$11.39
1-Wochen-Bereich:
$11.16
$11.88
52-Wochen-Spanne:
$7.44
$11.88
Theravance Biopharma Inc Stock (TBPH) Company Profile
Firmenname
Theravance Biopharma Inc
Sektor
Branche
Telefon
650-808-6000
Adresse
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Vergleichen Sie TBPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
11.23 | 576.52M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | Eingeleitet | BTIG Research | Buy |
| 2024-01-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-15 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-08-25 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-10-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | Eingeleitet | JP Morgan | Overweight |
| 2020-06-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-05-13 | Eingeleitet | Cowen | Outperform |
| 2020-01-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-06 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-29 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-05-11 | Bestätigt | Needham | Buy |
| 2016-12-21 | Eingeleitet | Needham | Buy |
| 2016-11-03 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-10-12 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | Eingeleitet | Guggenheim | Buy |
| 2016-06-20 | Bestätigt | Leerink Partners | Outperform |
| 2016-05-12 | Eingeleitet | Leerink Partners | Outperform |
| 2016-05-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
Alle ansehen
Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten
Exclusive: Theravance Biopharma Leadership Reveals Strategic Updates at BTIG Conference Next Week - Stock Titan
Is Theravance Biopharma Inc. a good long term investmentFast-track wealth growth - jammulinksnews.com
What analysts say about Theravance Biopharma Inc. stockExplosive trading growth - Autocar Professional
What drives Theravance Biopharma Inc. stock priceConsistent triple-digit returns - jammulinksnews.com
How Theravance Biopharma Inc. stock performs during market volatilitySecure Your Capital Strategy - Newser
Theravance Biopharma Inc. Stock Analysis and ForecastFree Daily Trading Room Entry - jammulinksnews.com
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail
Theravance Biopharma SVP Farnum sells $113,869 in stock By Investing.com - Investing.com Nigeria
Theravance Biopharma SVP Farnum sells $113,869 in stock - Investing.com
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail
What makes Theravance Biopharma Inc. stock price move sharplyStrategic High Profit Opportunities - Newser
Why Theravance Biopharma Inc. stock attracts strong analyst attentionFree Daily Stock Market Updates - Newser
Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma - Insider Monkey
Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Target Price at $16.60 - Defense World
Theravance Biopharma SVP Sells 7,000 Shares for $78,000 on July 14, 2025. - AInvest
Theravance higher as China approves Viatris-partnered COPD therapy - MSN
Theravance Biopharma (NASDAQ:TBPH) Downgraded to “Hold” Rating by Wall Street Zen - Defense World
Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from Russell 2000 Defensive Index - MarketScreener
Theravance Biopharma, Inc.(NasdaqGM: TBPH) added to Russell Microcap Growth Index - MarketScreener
Theravance Biopharma (NASDAQ:TBPH) Given New $25.00 Price Target at BTIG Research - Defense World
TBPH Stock Price Target Increased Following Milestone Payment | TBPH Stock News - GuruFocus
JonesTrading Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Theravance Biopharma price target raised to $25 by BTIG on China approval - Investing.com
Is Theravance Biopharma, Inc. technically bullish or bearish? - MarketsMojo
Theravance Biopharma (NASDAQ:TBPH) Now Covered by Jones Trading - Defense World
Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by Jones Trading - Defense World
Theravance Biopharma (TBPH) Receives New Analyst Coverage with a Buy Rating | TBPH Stock News - GuruFocus
(TBPH) Proactive Strategies - news.stocktradersdaily.com
Theravance Biopharma (TBPH) Gains Buy Rating with Promising Drug Prospects | TBPH Stock News - GuruFocus
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 32,534 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance and Mylan settle patent dispute with Eugia Pharma - MSN
theravance biopharma settles patent litigation with eugia pharma By Investing.com - Investing.com South Africa
Theravance and Viatris settle patent dispute with Eugia Pharma - Seeking Alpha
Theravance BiopharmaTheravance And Mylan Enter Settlement Agreement With EugiaSEC Filing - MarketScreener
Theravance Biopharma Settles Patent Litigation with Eugia - TipRanks
theravance biopharma settles patent litigation with eugia pharma - Investing.com
Finanzdaten der Theravance Biopharma Inc-Aktie (TBPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):